Original Article

You have full text access to this OnlineOpen article

Alterations of G1-S checkpoint in chordoma

The prognostic impact of p53 overexpression

  1. Takahiko Naka M.D.1,†,*,
  2. Carsten Boltze M.D.1,
  3. Doerthe Kuester M.D.1,
  4. Torss-Oliver Schulz M.D.1,
  5. Regine Schneider-Stock Ph.D.1,
  6. Angela Kellner Ph.D.1,
  7. Amir Samii M.D.2,
  8. Christian Herold M.D.2,
  9. Helmut Ostertag M.D.3,
  10. Albert Roessner M.D.1

Article first published online: 2 AUG 2005

DOI: 10.1002/cncr.21296

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1255–1263, 15 September 2005

Additional Information

How to Cite

Naka, T., Boltze, C., Kuester, D., Schulz, T.-O., Schneider-Stock, R., Kellner, A., Samii, A., Herold, C., Ostertag, H. and Roessner, A. (2005), Alterations of G1-S checkpoint in chordoma. Cancer, 104: 1255–1263. doi: 10.1002/cncr.21296

Author Information

  1. 1

    Department of Pathology, Faculty of Medicine, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

  2. 2

    Department of Neurosurgery, Nordstadt Medical Center, Klinikum Hanover, Hanover, Germany

  3. 3

    Department of Pathology, Nordstadt Medical Center, Klinikum Hanover, Hanover, Germany

  1. †

    Fax: (011) 81 934730627

*Department of Orthopedic Surgery, Kyushu Rosai Hospital, 1-3-1 Kuzuharatakamatsu, Kokuraminami-ku, Kitakyushu, Fukuoka, 800-0296, Japan

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 2 AUG 2005
  3. Manuscript Accepted: 25 APR 2005
  4. Manuscript Revised: 30 MAR 2005
  5. Manuscript Received: 27 JAN 2005

Funded by

  • Alexander von Humboldt Foundation, Germany

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (107K)

REFERENCES

  • 1
    Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759–767.
  • 2
    Greenblatt M, Benett W, Hollstein M, Harris C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855–4878.
  • 3
    Sherr C. Cancer cell cycles. Science. 1996; 274: 1672–1677.
  • 4
    Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol. 1994; 145: 287–293.
  • 5
    Ewen M, Sluss H, Sherr C, Matsushime H, Kato J, Livingston D. Functional interaction of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993; 73: 487–497.
  • 6
    Grana X, Reddy E. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKIs). Oncogene. 1995; 11: 211–219.
  • 7
    Naka T, Boltze C, Samii S, et al. Skull base and non-skull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003; 98: 1934–1941.
    Direct Link:
  • 8
    Cote R, Dunn M, Chatterjee S, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998; 58: 1090–1094.
  • 9
    Stefanaki K, Tzardi M, Kouvidou C, et al. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res. 1998; 18: 2403–2408.
  • 10
    Kohn GJ, Schwartz HJ, Buebner BH, Wong AJ, Lawson MJ. Colonic retinoblastoma protein and proliferation in cancer and non-cancer patients. J Gastroenterol Hepatol. 1997; 12: 198–203.
    Direct Link:
  • 11
    Ioachim E, Assimakopoulos D, Agnantis N, Peschos D, Zissi A, Skevas A. Altered patterns of retinoblastoma gene product expression in benign, premalignant and malignant epithelium of the larynx: an immunohistochemical study including correlation with p53, bcl-2 and proliferating indices. Anticancer Res. 1999; 19: 541–546.
  • 12
    Schneider-Stock R, Haeckel C, Radig K, Pein C, Roessner A. Improved detection of p53 mutations in soft tissue tumors using new gel composition for automated non radioactive analysis of single-strand conformation polymorphism. Electrophoresis. 1997; 18: 2849–2851.
    Direct Link:
  • 13
    Goldmann D, Merril C. Silver staining of DNA in polyacrylamide gels: linearity and effect of fragment size. Electrophoresis. 1982; 3: 24–26.
    Direct Link:
  • 14
    Bergh P, Kindblom L, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom J. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000; 88: 2122–2134.
    Direct Link:
  • 15
    Pallini R, Maira G, Pierconti F, et al. Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg. 2003; 98: 812–822.
  • 16
    Chehab N, Malikzay A, Appel M, Halazonetis T. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev. 2000; 14: 278–288.
  • 17
    Shieh S, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000; 14: 289–300.
  • 18
    Shieh S, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997; 91: 325–334.
  • 19
    Honda R, Yasuda, H. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999; 18: 22–27.
  • 20
    Tao W, Levine AJ. p19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 1999; 96: 6937–7941.
  • 21
    Zhang Y, Xiong Y, Yarbrough W. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4A locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998; 92: 725–734.
  • 22
    Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA. 1999; 96: 14973–14977.
  • 23
    Cordon-Cardo C, Lastres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994; 54: 794–799.
  • 24
    Lianes P, Orlow I, Zhang Z, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994; 86: 1325–1330.
  • 25
    Capoulade C, Bressac-de Paillerets B, Lefrere I, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 1998; 16: 1603–1610.
  • 26
    Foster C, Lozano G. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002; 21: 3525–3531.
  • 27
    Shvarts A, Steegenga W, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996; 15: 5349–5357.
  • 28
    Riemenschneider M, Buschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999; 59: 6091–6096.
  • 29
    Landers J, Haines D, Strauss JI, George D. Enhanced translation: a novel mechanism of mdm2 oncoprotein overexpression identified in human tumor cells. Oncogene. 1994; 9: 2745–2750.
  • 30
    Olson D, Marechal V, Momand J, Chen J, Romocki C, Levine A. Identification and characterization of multiple mdm2 proteins and mdm2 p53 protein complexes. Oncogene. 1993; 8: 2353–2360.
  • 31
    Wurl P, Meye A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 1998; 16: 1183–1185.
  • 32
    Patterson H, Gill S, Fisher C, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer. 1994; 69: 1052–1058.
  • 33
    Jones S, Hancock A, Vogel H, Donehower L, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA. 1998; 22: 15608–15612.
  • 34
    Sigalas I, Calvert A, Anderson J, Neal D, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med. 1996; 2: 912–917.
  • 35
    Cordon-Cardo C, Zhang Z, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997; 57: 1217–1221.
  • 36
    Oshiro Y, Chaturvedi V, Hayden D, et al. Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study. Cancer. 1998; 83: 2324–2334.
    Direct Link:
  • 37
    de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer. 2000; 89: 783–792.
    Direct Link:
  • 38
    Taubert H, Meye A, Wurl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 1996; 56: 4134–4136.
View Full Article (HTML) Get PDF (107K)